Lead Product(s) : PBI-200
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Molecular Intelligence Trials (MI Trials) collaboration will enhance identification of patients with NTRK fusion-positive solid tumors, including primary and metastatic CNS tumors potentially eligible for enrollment in the ongoing PBI-200-101 Phase 1/2 c...
Product Name : PBI-200
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 03, 2022
Lead Product(s) : PBI-200
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Caris Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PBI-200
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDA
Details : PBI-200 is an oral, highly potent, and selective inhibitor of TRK kinase that is currently in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases.
Product Name : PBI-200
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2022
Lead Product(s) : PBI-200
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
